Gallatin Valley Vision, Llc | |
9 E Birch St, Three Forks, MT 59752 | |
(406) 285-6901 | |
(406) 285-6511 |
Full Name | Gallatin Valley Vision, Llc |
---|---|
Type | Facility |
Speciality | Optometrist |
Location | 9 E Birch St, Three Forks, Montana |
Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1477218188 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
152W00000X | Optometrist | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Gallatin Valley Vision, Llc Po Box 1008, Three Forks, MT 59752-1008 Ph: (406) 285-6901 | Gallatin Valley Vision, Llc 9 E Birch St, Three Forks, MT 59752 Ph: (406) 285-6901 |
News Archive
TraceLink, Inc., the provider of the World's 1st Industry-Wide Supply Collaboration Network, and Catalent Pharma Solutions, Inc., a leading provider of innovative drug development and delivery solutions for pharmaceutical, biotechnology and consumer healthcare companies, today announced a partnership that will improve production visibility for Catalent customers across their entire manufacturing and packaging product lifecycle.
Fleming Pharmaceuticals, maker of ThyroShield– the only FDA approved liquid potassium iodide product indicated for thyroid protection in radiation emergencies – announced today that it has implemented the changes necessary to ramp up production to meet increased domestic and international demand.
The World Health Organization is calling on belligerents in Syria to allow for the immediate and safe evacuation of the sick and wounded from all areas affected by the conflict, including eastern Aleppo.
Foundation Medicine, Inc. and Clovis Oncology, Inc. announced today that they have entered into a diagnostic collaboration.
Sesen Bio, Inc., a late-stage clinical company developing fusion protein therapies for the treatment of cancer, today announced that the company will present its three-month Phase 3 VISTA Trial data during a poster session at the Global Congress on Bladder Cancer 2018.
› Verified 5 days ago